FDA meta-analysis indicates no cancer risk with angiotensin receptor blockers
This article was originally published in Scrip
Executive Summary
The US FDA determined that angiotensin receptor blockers, such as AstraZeneca's Atacand (candesartan), Daiichi Sankyo's Benicar (olmesartan) and Bristol-Myers Squibb's and Sanofi's Avapro (irbesartan), do not increase the risk of developing cancer.